Small molecule · Inhibitor of isocitrate dehydrogenase 1 (IDH1) (IDH1) · developed by Rigel Pharms
Olutasidenib is a small-molecule inhibitor of mutated isocitrate dehydrogenase-1 (IDH1), acting on mutant IDH1 enzymes such as R132H and R132C to reduce levels of 2-hydroxyglutarate in leukemia cells. It is used for acute myeloid leukemia with susceptible IDH1 mutations and is being studied in glioma, cholangiocarcinoma and other solid tumor malignancies.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Nov 5, 2025). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07486713 | Phase 4 | AML (Acute Myeloid Leukemia) | Recruiting | RIGL |
| NCT07130695 | Phase 1 | Acute Myeloid Leukemia | Withdrawn | RIGL |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
AML (Acute Myeloid Leukemia)CholangiocarcinomaGliomaSolid Tumor MalignanciesAcute Myeloid Leukemia
Updated Nov 8, 2026. Something wrong or missing? Report it on the RIGL page.
See RIGL's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
RIGL catalysts and pipeline →